Stockscreener 앱 받기
258.13
4.74%
-12.85
시간 외 거래:
261.80
3.67
+1.42%
전일 마감가:
$270.98
열려 있는:
$271
하루 거래량:
597.79K
Relative Volume:
0.61
시가총액:
$6.46B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-28.15
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+44.11%
1개월 성능:
+53.45%
6개월 성능:
+479.94%
1년 성능:
+287.82%
1일 변동 폭
$256.50
$278.44
1주일 범위
$180.46
$278.44
52주 변동 폭
$26.70
$278.44
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
258.13 | 6.78B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
692.58 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.21 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.41 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.17 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - Seeking Alpha
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Finviz
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Nigeria
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com UK
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data By Investing.com - Investing.com South Africa
PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus
Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus
Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times
Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating - marketscreener.com
HC Wainwright Reiterates 'Buy' Rating on PRAX with $340 PT | PRA - GuruFocus
Praxis (NASDAQ: PRAX) posts 53% seizure drop in EMBOLD trial, plans FDA NDA talks - Stock Titan
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data - Investing.com Australia
BTIG Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX: BTIG Raises Price Target to $507 with Buy Rating | PRAX St - GuruFocus
Praxis Precision Medicines (PRAX) Gaining Confidence on EMBOLD Study Optimism - Insider Monkey
Kennedy Capital Management LLC Increases Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week HighWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone - Yahoo Finance
Capital Fund Management S.A. Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicine (PRAX) Target Price Raised by HC Wainw - GuruFocus
Praxis Precision Medicines stock hits 52-week high at $241.0 By Investing.com - Investing.com Nigeria
HC Wainwright & Co. maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Potential Breakthrough: Market Reactions - StocksToTrade
Another Praxis win provides much-needed progress in rare genetic epilepsies - BioCentury
PRAX Announces Breakthroughs in Neurological Treatments: Key Developments with FDA - StocksToTrade
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.50%
자본화:
|
볼륨(24시간):